The FDA’s approval was based on data from the EXPLORER-HCM trial, which showed that mavacamten was superior to a placebo for treating obstructive HCM and associated with no significant long-term, treatment-related adverse events.

New data from the STROKE AF clinical trial shows large and small vessel ischemic stroke patients who receive short-term or intermittent monitoring with Holter and 30-day external monitors had fewer AFib episodes detected that continuous implantable cardiac monitors.

It has been a busy few weeks for the FDA, with plenty of big-name approvals and recalls making the news, but there have also been some other big announcements related to solutions receiving FDA clearance. 

Heart Rhythm 2022, held from April 28 to May 1 in San Francisco, included a wide range of studies presented by some of the industry's leading specialists. 

Another single-chamber leadless pacemaker has officially hit the market. 

Mass General cardiologist and Harvard professor Ami Bhatt, MD, predicts upcoming paradigm shifts in cardiology over the next decade. 

A large proportion of patients with atrial fibrillation (AFib) end up in emergency rooms (ERs), but there are inherent issues with most hospital ERs handing off these patients to electrophysiologists for follow-up care.

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.